RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Theravance Biopharma - Stock

Theravance Biopharma Net Income 2024

Theravance Biopharma Net Income

-32.31 M USD

Ticker

TBPH

ISIN

KYG8807B1068

WKN

A1137V

In 2024, Theravance Biopharma's profit amounted to -32.31 M USD, a -41.46% increase from the -55.19 M USD profit recorded in the previous year.

The Theravance Biopharma Net Income history

YEARNET INCOME (undefined USD)
2029e229.91
2028e137.9
2027e70.93
2026e43.75
2025e6.12
2024e-32.31
2023-55.19
2022872.1
2021-199.4
2020-278
2019-236.5
2018-215.5
2017-285.4
2016-190.7
2015-182.2
2014-237
2013-156.3
2012-9.6
2011-109.3

Theravance Biopharma Aktienanalyse

What does Theravance Biopharma do?

Theravance Biopharma Inc is a company that was founded in 2014 and is headquartered in South San Francisco, California. The company is a spin-off of Theravance Inc, which was founded in 1996 and specialized in the development of drugs for respiratory diseases and infections. The business model of Theravance Biopharma is to develop and market innovative drugs for severe respiratory diseases, infections, and immunological disorders. The company works closely with its partners and scientific network to discover, develop, and market new drugs. Theravance Biopharma is divided into several business units, including Theravance Biopharma R&D, which focuses on drug discovery and development, and Theravance Biopharma Commercialization, which focuses on marketing Theravance's products. The company has developed and launched a number of products, including the branded products Vibativ and Velusetrag. Vibativ is an antibiotic used to treat severe lung infections and other infections, while Velusetrag was developed for the treatment of chronic constipation in patients with gastrointestinal disorders such as irritable bowel syndrome. The company also has a broad pipeline of products in various stages of development. This includes drugs for the treatment of asthma and chronic obstructive pulmonary disease (COPD), autoimmune and inflammatory diseases such as Crohn's disease and ulcerative colitis, as well as infections such as MRSA and pneumococcal. Theravance Biopharma has also formed a strong partnership with GSK (GlaxoSmithKline), one of the world's leading pharmaceutical companies. The two companies are working together to develop drugs to help patients with severe respiratory diseases, infections, and immune disorders. In summary, Theravance Biopharma is an innovative company that focuses on the discovery, development, and commercialization of drugs for the treatment of severe respiratory diseases, infections, and immune disorders. The company has a strong pipeline of products in various stages of development and a strong partnership with GSK to continue providing innovative solutions for patients with severe illnesses. Theravance Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Theravance Biopharma's Profit Margins

The profit margins of Theravance Biopharma represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Theravance Biopharma's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Theravance Biopharma's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Theravance Biopharma's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Theravance Biopharma’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Theravance Biopharma Stock

How much profit has Theravance Biopharma made this year?

Theravance Biopharma has made -32.31 M USD this year.

How has the profit developed compared to last year?

The profit has increased by -41.46% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Theravance Biopharma publish its earnings?

Theravance Biopharma publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Theravance Biopharma?

The profits of Theravance Biopharma are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Theravance Biopharma?

You can learn more about the earnings of Theravance Biopharma by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Theravance Biopharma pay?

Over the past 12 months, Theravance Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Theravance Biopharma is expected to pay a dividend of 0 USD.

What is the dividend yield of Theravance Biopharma?

The current dividend yield of Theravance Biopharma is .

When does Theravance Biopharma pay dividends?

Theravance Biopharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Theravance Biopharma?

Theravance Biopharma paid dividends every year for the past 0 years.

What is the dividend of Theravance Biopharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Theravance Biopharma located?

Theravance Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Theravance Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Theravance Biopharma from 6/11/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/11/2024.

When did Theravance Biopharma pay the last dividend?

The last dividend was paid out on 6/11/2024.

What was the dividend of Theravance Biopharma in the year 2023?

In the year 2023, Theravance Biopharma distributed 0 USD as dividends.

In which currency does Theravance Biopharma pay out the dividend?

The dividends of Theravance Biopharma are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Theravance Biopharma

Our stock analysis for Theravance Biopharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Theravance Biopharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.